single invest

Isanans Pharma

Isanans Pharma is a biopharmaceutical company focusing on inflammatory eye disorders. Lead asset is a small molecule KCa3.1 channel blocker which has demonstrated significant anti-inflammatory effect in vivo while not causing any adverse effects.

Isanans Pharma has been a part of the Accelerace accelerator program, that help startup companies accelerate and scale up their business model and finetune their companies. Isanans Pharma is one of more than 500 companies that Accelerace already have accelerated.

Related startups